FUNDAMENTALS |
MarketCap: |
737 039 mill
|
EPS: |
6.82
|
P/E: |
113.71
|
Earnings Date: |
Aug 08, 2024 |
SharesOutstanding: |
950.41 mill
|
Avg Daily Volume: |
2.90 mill
|
RATING
2024-05-08 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
7.37x
|
Company: PE 113.71 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
4.71x
|
Company: PE 113.71 | industry: PE 24.13
|
DISCOUNTED CASH FLOW VALUE |
$279.25
(-63.99%)
$-496.25
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 756.92 - 793.52
( +/- 2.36%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-15 | Sulzberger Gabrielle | Buy | 13 | Common Stock |
2024-04-15 | Luciano Juan R | Buy | 20 | Common Stock |
2024-04-15 | Johnson Kimberly H | Buy | 13 | Common Stock |
2024-04-15 | Hedley Mary Lynne | Buy | 13 | Common Stock |
2024-04-15 | Alvarez Ralph | Buy | 16 | Common Stock |
INSIDER POWER |
-42.39
|
Last
100 transactions |
Buy:
207 692 | Sell:
512 083 |
Forecast:
12:00 - $779.66
Live Trading Signals (every 1 min)
Forecast
1: 10:30 - $775.05
Forecast 2: 11:20 - $778.36
Forecast 3: 12:00 - $779.66
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$775.50 (0.06% )
|
Volume |
0.617 mill
|
Avg. Vol. |
2.90 mill
|
% of Avg. Vol |
21.23 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For LLY
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.